IGC Pharma, Inc.

Equities

IGC

US45408X3089

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:40:00 11/05/2024 am IST			5-day change	1st Jan Change
0.515 ^USD	-0.96%		+0.74%	+83.86%

16/04	IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo	CI
22/03	Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	MT

IGC PHARMA : Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

April 26, 2024 at 09:14 pm IST

IGC Pharma Advances in Alzheimer's Research from Pre-clinical Studies to Phase Two Trials with its Novel Therapy Candidate IGC-AD1 By: Faith Ashmore Benzinga Staff Writer Alzheimer's disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact Read More [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

Original Link
Permalink

Disclaimer

IGC Pharma Inc. published this content on 26 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 April 2024 15:41:45 UTC.

Latest news about IGC Pharma, Inc.

IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo	16/04	CI
Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	22/03	MT
Aurora Cannabis, Canopy Growth Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	22/03	MT
IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited	22/03	CI
IGC Pharma, Inc Announces the Results of an Interim Analysis of its Ongoing Phase 2 Trial Investigating IGC-Ad1 as Treatment for Agitation in Dementia from Alzheimer?s Disease	20/03	CI
Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors	13/03	CI
IGC Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	15/02	CI
IGC Pharma Announces Tgr-63 Reduces Agitation in Alzheimer's Mouse Model	01/02	CI
IGC Pharma, Inc. Provides Details on its Drug Candidate TGR-63	23/01	CI
Igc Pharma, Inc. Activates Clincloud, One of 12 Sites in Ongoing Phase 2B Alzheimer?S Trial	17/01	CI
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's	19/12	CI
IGC Pharma, Inc. Announces an Artificial Intelligence Collaboration with Los Andes University?s Center for Research and Training in Artificial Intelligence	06/12	CI
IGC Pharma, Inc. Announces Master Agreement with University of Los Andes to Advance AI Initiatives	21/11	CI
Earnings Flash (IGC) IGC PHARMA Posts Q2 Revenue $291,000	13/11	MT
IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	10/11	CI
IGC Pharma Receives European Patent for Cannabinoid Pain Treatment	20/23/20	MT
North American Morning Briefing : Treasury Yields Keep Pushing Higher	17/23/17	DJ
Earnings Flash (IGC) IGC PHARMA Reports Q1 Revenue $555,000	14/23/14	MT
IGC Pharma, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
IGC Pharma Expands Phase 2 Trial of IGC-Ad1 to Include the University of Puerto Rico	02/23/02	CI
IGC Pharma, Inc. Presents 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference	18/23/18	CI
IGC Pharma, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	08/23/08	CI
IGC Pharma, Inc. Enters into Master Loan and Security Agreement	07/23/07	CI
IGC Pharma to Raise $3 Million in Gross Proceeds From Private Placement	06/23/06	MT
IGC Pharma, Inc. announced that it expects to receive $3 million in funding	06/23/06	CI

Chart IGC Pharma, Inc.

Duration

Period

More charts

Company Profile

IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimerâs disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimerâs disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimerâs cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimerâs disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimerâs. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimerâs cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Sector

Biotechnology & Medical Research

Calendar

20/06/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.515 USD

Average target price

3.25 USD

Spread / Average Target

+531.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IGC PHARMA, INC.	+83.86%	34.02M
MODERNA, INC.	+17.96%	44.96B
LONZA GROUP AG	+48.77%	41.85B
IQVIA HOLDINGS INC.	+1.17%	42.65B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research